Nasal Nitric Oxide Composition for Viral Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively enhance the synthesis of nasal nitric oxide and lung surfactants, leading to increased severity and duration of viral infections, cytokine storms, lung fibrosis, and hypoxemia, particularly in patients with conditions like COVID-19 and asthma, due to decreased synthesis of these molecules.
Innovation Solution
A method involving the application of a composition containing sodium pyruvate, calcium phosphate, and magnesium chloride to stimulate the synthesis of nasal nitric oxide and lung surfactants, preventing viral docking to ACE2 receptors and reducing cytokine storms, comprising a therapeutically effective amount of sodium pyruvate ranging from 0.0001 mg to 1 gram, along with calcium and magnesium salts, in a saline solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for viral infections, then viral replication and spread are not effectively controlled, but the severity and duration of infections increase along with cytokine storms and lung fibrosis
Solution Approach 1:
The composition is applied topically to the nasal cavity and lungs before viral infection fully establishes, creating a preventive layer of nitric oxide and surfactants that block viral docking to ACE2 receptors. This preliminary action prevents viral replication before it can spread systemically, thereby reducing both severity and duration of infection.
Solution Approach 2:
Nasal nitric oxide acts as an intermediary substance that blocks the interaction between the virus and ACE2 receptors on host cells. The composition stimulates endogenous production of this intermediary, which then prevents viral docking and replication without directly confronting the virus, thereby reducing infection severity and duration.
2Object-affected harmful factors
If nasal nitric oxide and lung surfactants are not synthesized adequately, then viral docking to ACE2 receptors increases, but this leads to increased severity and duration of infections
Solution Approach 1:
The composition contains precursors and stimulants that trigger the body's own cells to produce nasal nitric oxide and lung surfactants. Rather than administering these substances directly, the formulation enables endogenous production, allowing the body to self-generate the protective factors needed to block viral docking and enhance infection resistance.
Solution Approach 2:
The composition alters the concentration parameters of nasal nitric oxide and lung surfactants by providing biochemical precursors and stimulation. This parameter change increases the availability of these protective molecules at the mucosal surfaces, thereby enhancing the body's ability to prevent viral docking and improve infection resistance.
3Reliability
If lung surfactants are decreased, then lung function and oxygen saturation deteriorate, but this also increases susceptibility to viral infections
Solution Approach 1:
Lung surfactants serve multiple functions: they maintain lung compliance and oxygen saturation while also blocking viral docking to ACE2 receptors. The composition stimulates production of this multi-functional substance, thereby simultaneously improving lung function and increasing resistance to viral infection through the same endogenous surfactant layer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the replication, severity, and duration of viral infections, decreases lung fibrosis, and improves lung function by enhancing oxygen saturation and reducing symptoms such as coughing and breathlessness in patients with various respiratory conditions.
Implementation Method 1
stimulating the synthesis of nasal nitric oxide and lung surfactants that are decreased by diabetes, lung diseases, cancer, infections and other ailments
Implementation Method 2
which inhibit the docking of CIVID-19 to cellular receptors, like ACE2
Data Source
AI summary
A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.